Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Synplogen and Ginkgo Bioworks have announced a collaboration to expedite DNA manufacturing and gene therapy services in Japan. Synplogen will facilitate the introduction of Ginkgo's services to the Japanese biotech and pharmaceutical sectors.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 10:08 pm

Vivici BV, a Dutch B2B ingredients company, has partnered with Ginkgo Bioworks Holdings Inc (NYSE:DNA) to develop and commercialize alternative dairy proteins using precision fermentation. Ginkgo will provide optimized strains for dairy protein production, which Vivici will use to expand their protein range for specialized nutrition companies. Ginkgo's Protein Production Services and AI platform will be utilized in the process. DNA shares saw a slight decrease of 0.68% to $1.45 in premarket trading.

Portfolio Pulse from Shivani Kumaresan

November 27, 2023 | 1:11 pm

Vivici has partnered with Ginkgo Bioworks to develop and commercialize a new generation of functional alternative dairy proteins using Ginkgo's strain engineering and optimization expertise.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:06 pm

Vivici BV has partnered with Ginkgo Bioworks to enhance the production of sustainable and nutritious dairy protein through precision fermentation. Ginkgo will leverage its Protein Production Services and generative AI platform to provide optimal candidate strains for Vivici, which will help extend their protein range and support specialized nutrition companies in delivering eco-friendly nutrition options to consumers.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 9:07 am

Raymond James analyst Rahul Sarugaser has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Outperform to Market Perform and set a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 4:51 pm

Raymond James analyst Rahul Sarugaser has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Outperform to Market Perform and set a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 3:45 pm

The article lists the stocks that gained and lost the most in Thursday's mid-day session. Among the gainers were Intelligent Bio Solutions Inc., Astra Space, Inc., and Tempest Therapeutics, Inc., which saw significant increases due to positive quarterly results and acquisition proposals. Among the losers were Enviva Inc., ContraFect Corporation, and Atara Biotherapeutics, Inc., which saw significant decreases due to poor quarterly results and disappointing clinical trial outcomes.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:13 pm

Ginkgo Bioworks reported mixed Q3 financial results, leading to a decrease in its stock value. Following the earnings report, BTIG downgraded the stock from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:41 pm

BTIG analyst Mark Massaro has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 2:32 pm

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q3 losses of $(0.16) per share, missing the analyst consensus estimate of $(0.09) by 77.78%. However, the company's quarterly sales of $55.43 million beat the analyst consensus estimate of $48.08 million by 15.29%. This represents a 60.98% increase in losses and a 16.52% decrease in sales compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

November 08, 2023 | 10:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.